Navigation Links
Fewer adverse cardiac events at one year
Date:10/23/2007

WASHINGTON, DC OCTOBER 22, 2007 Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

The rate of the primary endpoint, in-segment late loss (a measure of how much the artery re-narrows following stenting) was also reduced by 50% with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure (a combination of repeat procedures anywhere in the involved blood vessel and adverse cardiac events), as well as stent thrombosis (dangerous blood clots that can form within the stent).

Both the primary endpoint of the trial and the major secondary endpoint were met, said Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center. Moreover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease. Given this positive finding, which has never before been seen in a pivotal drug-eluting stent vs. stent trial, coupled with the ease of use of Xience, will result in this device becoming a favored drug-eluting stent for clinicians treating coronary disease.

Further studies are required to determine whether there are meaningful differences between the two stent types in low frequency safety events, and in important subgroups, Stone added.

SPIRIT III 12-Month Results

Everolimus-Eluting Stent Paclitaxel-Elu
'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Chemotherapy Pill Has Fewer Side Effects Than IV
2. Fewer teeth & Increased Ischemic Stroke risk
3. Heart Patients More At Risk Get Fewer Medicines
4. Fewer People Die Due To Cancer
5. Fewer Breast Cancer Patients to Get Chemo
6. Fewer Blacks Undergo Lung Cancer Surgery
7. Thailand had Fewer AIDS-Related Deaths, New HIV Cases In 2005
8. Fewer Neurons in Amygdala of Autistic Males
9. Women With Fewer Periods Have Low Risk Of Gynecological Cancer
10. Fewer Doctors Treating For Free
11. Fruits & Vegetables Makes You Look Younger With Fewer Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Sunrise, FL (PRWEB) July 14, 2014 ... announced the expansion of its Quality Control and Assurance ... Formulations has hired two additional, highly-qualified quality assurance (QA) ... superior product standards for which IQ Formulations has become ... and QC technicians bring decades of stellar experience and ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
(Date:7/14/2014)... Francisco, California (PRWEB) July 14, 2014 ... expected to reach USD 4,285.1 million by 2020 ... a new study by Grand View Research, Inc. ... computational biology for bioinformatics R&D programs designed for ... increasing number of clinical studies in pharmacogenomics and ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6
... 7- to ... 9-hour flights, HOBOKEN, N.J., Nov. ... Pycnogenol(R), pine bark,extract from the French maritime pine tree, reduces jetlag in ... scan and a,scoring system, showed Pycnogenol(R) lowered symptoms of jetlag such as,fatigue, ...
... N.J., Nov. 5 BD (Becton,Dickinson and Company) (NYSE: ... for the fourth fiscal quarter ended September 30, 2008,representing ... period. This,quarter,s growth rate reflects the favorable impact on ... to account for 5,percentage points of the increase in ...
... Simulation and Education Conference (I/ITSEC) has sold ... County Convention Center in Orlando. Occupying almost 200,000 ... modeling and simulation technology ever. The I/ITSEC ... 2008 at the Orange County Convention Center in ...
... qualified health insurance underwriters, much of the frustration associated with filling ... serve to not only comfort users, but expedite the entire process, ... ... CA (PRWEB) November 5, 2008 -- Internet based insurance agency, TheHealthQuote, ...
... review outlines potential pharmaceutical, dietary, surgical, and other ... among women in the United States, and examines ... risk reduction strategies for women at average risk ... factors. Among the recommendations: aside from following general ...
... six hours of,deliberation, a Broward County Jury awarded a ... secondhand exposure case. Lynda and Michael Daly,claimed that Mrs. ... asbestos-containing brakes manufactured by Ford Motor Co. and,Pneumo Abex. ... was diagnosed in,May of 2007 and has been a ...
Cached Medicine News:Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 2Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 3Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 5Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 6Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 7Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 8Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 9Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 10Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 11Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 12Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 13Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 14Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 2Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 3Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 2Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 3
(Date:7/14/2014)... Calif. , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on ... ("SEC") by Mallinckrodt plc on May 16, 2014 and amended ... of Mallinckrodt and Questcor that also constitutes a prospectus of ... statement on Form S-4 is available on the SEC,s EDGAR ...
(Date:7/14/2014)... 2014 BioAdaptives, Inc. (OTCBB:BDPT) is pleased to ... the roles of President and CEO of the Company.  ... the company that licensed its formulation, intellectual properties, and ... "Mr. Gerald Epling , who ... a privately held entity to a public company, has ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Medicine Products: